Identification of the first-in-class dual inhibitors of human DNA topoisomerase IIα and indoleamine-2,3-dioxygenase 1 (IDO 1) with strong anticancer properties

Author:

Kaproń Barbara1ORCID,Płazińska Anita2,Płaziński Wojciech23,Plech Tomasz4ORCID

Affiliation:

1. Department of Clinical Genetics, Medical University of Lublin, Lublin, Poland

2. Department of Biopharmacy, Medical University of Lublin, Lublin, Poland

3. Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Cracow, Poland

4. Department of Pharmacology, Medical University of Lublin, Lublin, Poland

Funder

National Science Centre, Poland

IDO1/IDO2/TDO

statutory fund

Medical University of Lublin

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Reference23 articles.

1. [accessed 23 May 2022] https://www.who.int/news-room/fact-sheets/detail/cancer

2. [accessed 23 May 2022] https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf

3. European cancer mortality predictions for the year 2022 with focus on ovarian cancer

4. [accessed 23 May 2022] https://www.nih.gov/news-events/news-releases/cancer-costs-projected-reachleast-158-billion-2020

5. Targeting DNA topoisomerase II in cancer chemotherapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3